{"id":"NCT04797650","sponsor":"Concert Pharmaceuticals","briefTitle":"Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-10","primaryCompletion":"2022-06-08","completion":"2022-06-29","firstPosted":"2021-03-15","resultsPosted":"2023-07-03","lastUpdate":"2023-07-03"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alopecia Areata"],"interventions":[{"type":"DRUG","name":"CTP-543 matching placebo","otherNames":[]},{"type":"DRUG","name":"CTP-543","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"CTP-543 8 mg BID","type":"EXPERIMENTAL"},{"label":"CTP-543 12 mg BID","type":"EXPERIMENTAL"}],"summary":"This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.","primaryOutcome":{"measure":"Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score â‰¤20 at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.8,"sd":null},{"arm":"CTP-543 8 mg BID","deltaMin":33,"sd":null},{"arm":"CTP-543 12 mg BID","deltaMin":38.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":63,"countries":["United States","Canada","France","Germany","Hungary","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":130},"commonTop":["COVID-19","Asymptomatic COVID-19","Nasopharyngitis","Headache","Acne"]}}